{"id":45757,"date":"2025-11-04T21:21:35","date_gmt":"2025-11-04T13:21:35","guid":{"rendered":"https:\/\/flcube.com\/?p=45757"},"modified":"2025-11-04T21:21:36","modified_gmt":"2025-11-04T13:21:36","slug":"nhsa-re%e2%80%91designs-drug%e2%80%91prescribing-surveillance-targeting-illicit-use-and-resale","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45757","title":{"rendered":"NHSA Re\u2011designs Drug\u2011Prescribing Surveillance, Targeting Illicit Use and Resale"},"content":{"rendered":"\n

The National Healthcare Security Administration issued a comprehensive notice to strengthen the intelligent monitoring of excessive drug prescribing<\/strong>. The directive sets a phased timeline for nationwide coverage, mandates inclusion of high\u2011risk pharmacy items, and frames the analytical rules around three drug categories and behavior patterns.<\/p>\n\n\n\n

Timeline & Coverage Milestones<\/h3>\n\n\n\n
Deadline<\/th>Scope<\/th>Objective<\/th><\/tr><\/thead>
Dec\u202f2025<\/strong><\/td>50 key monitored medical\u2011insurance drugs in pilot regions<\/td>Establish initial intelligent\u2011monitoring framework<\/td><\/tr>
Jun\u202f2026<\/strong><\/td>100 key monitored drugs nationwide<\/td>Expand provincial coverage<\/td><\/tr>
Dec\u202f2026<\/strong><\/td>Full coverage of all key drugs<\/td>Institute uniform national rules and seamless data\u2011integration across screening, alerts, and enforcement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Categories Under Focus<\/h3>\n\n\n\n
    \n
  1. Financially aberrant drugs<\/strong> \u2013 those linked to illegal or irregular claims.<\/li>\n\n\n\n
  2. Cost\u2011driven drugs<\/strong> \u2013 top\u2011payer items from the pooling fund with abnormal expenditure curves.<\/li>\n\n\n\n
  3. High\u2011margin resale drugs<\/strong> \u2013 popular items with substantial resale appeal and profit spreads.<\/li>\n<\/ol>\n\n\n\n

    Abnormal Purchasing Behaviors<\/h3>\n\n\n\n